Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

41 results about "Plasmid transfection" patented technology

Plasmid transfection. Plasmids are small circular DNA molecules that are commonly found in bacteria. They exist and replicate separately from chromosomal DNA and in bacteria they often carry genes that are beneficial for bacterial survival. Plasmids can be deliberately introduced into desired cells and utilized to overexpress a gene...

Method for rapidly constructing IgG antibody high-expression stably-transfected CHO cell strain

The invention is applicable to the technical field of biotechnology and cell biology, and provides a method for quickly constructing an IgG antibody high-expression stably-transfected CHO cell strain, which comprises the following steps: S1, constructing antibody plasmids; s2, carrying out cell resuscitation, passage and plasmid transfection; s3, screening positive cells; s4, preparing, namely screening high-expression stably transfected single cell clones; s5, cell feeding batch culture; s6, verifying the stability of the cell strain expressed by the antibody, according to the method provided by the invention, after the plasmid vector enters the cell through electrotransfection and standing culture is carried out for 48 hours, shaking culture is carried out, the cell recovery time can be shortened, the recovery speed is higher than that of traditional standing culture, and the cell state is better than that of a standing state; according to the method, high-density cells are inoculated during cell fed-batch culture, and under the high-density inoculation, the logarithmic phase of the cells is shortened, and the cells enter a protein production phase earlier, so that higher expression quantity can be achieved, the overall production period is greatly shortened, and a large amount of cost is saved.
Owner:ZHEJIANG LONGI BIOTECHNOLOGY CO LTD

Porcine epidemic diarrhea virus recombinant strain, construction method and application

The application belongs to the technical field of biotechnology, and particularly relates to a porcine epidemic diarrhea virus recombinant strain, a construction method and application. The S gene sequence of the existing epidemic porcine epidemic diarrhea virus PEDV CH / SX / 2016 strain is replaced by the S2015 gene sequence shown in SEQ ID NO. 1 to construct a PEDV CH / SX / 2016 strain infectious clone. A porcine epidemic diarrhea virus recombinant strain rCH / SX / 2016-S 2015 is successfully rescued by transfecting cells with a plasmid containing the infectious cDNA shown in SEQ ID NO. 4. The problem that the original strain cannot be successfully rescued by reverse genetics engineering is solved, and the recombinant virus strain rCH / SX / 2016-S 2015 has an activity comparable to that of the original strain, and can be used for preparing a PEDV diagnostic reagent and / or vaccine.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER) +1

FLP-IN-PIEC cell line as well as construction method and application thereof

The invention relates to the related technical field of molecular biology and cell engineering, in particular to an FLP-IN-PIEC cell line and a construction method and application thereof, and the construction method comprises the following steps: step 1, constructing CRISPR / Cas9 site-specific cleavage plasmid containing a pig HIPP11 safety site sequence; step 2, constructing a donor plasmid Donor-FRT containing a homologous arm of a safety site of the HIPP11; 3, jointly transfecting plasmids in the step 1 and the step 2 into a porcine hip artery endothelial cell line (PIEC) to obtain an FLP-IN-PIEC cell line for expressing red fluorescence; and 4, under the action of Flp recombinase, transfecting an exogenous gene donor plasmid containing an FRT site to the FLP-IN-PIEC cell line obtained in the step 3, and driving the expression of a target gene through an optimized strong promoter to realize fixed-point transfer and efficient expression of the exogenous gene in the pig (PIEC) cell line. Different from an existing Flp-In system depending on a random integration strategy, the construction method disclosed by the invention emphasizes fixed-point integration and promoter optimization, and improves the homogeneity, stability and screening efficiency of exogenous gene expression.
Owner:CHINA AGRI UNIV

Blocking agent for cell immunofluorescence detection by slide method and use method of blocking agent

The invention discloses a blocking agent for cell immunofluorescence detection by a slide method and a use method of the blocking agent. The blocking agent is a homologous no-load cell lysis solution without transfection plasmids, and the protein concentration is greater than or equal to 30mg / mL. The blocking agent is completely the same as cell cytoplasm and cell membrane components of cells to be detected except for plasmids-expressed antigens, when in use, the blocking agent is pre-mixed with a blood cleaning sample in advance, interfering antibodies except target antibodies in serum can be purified, and meanwhile, due to the fact that no antigen protein expressed after plasmid transfection exists, the blocking agent can be used for detecting the cells to be detected. And the protein concentration is equivalent to the globulin concentration in serum, so that the target antibody cannot be lost in the serum, and the slide method CBA detection sensitivity can be greatly improved.
Owner:BEIJING JINGYI MEDICAL TESTING LAB CO LTD

Tissue culture-free genetic transformation method of coastal chrysanthemum indicum mediated by agrobacterium rhizogenes and application of tissue culture-free genetic transformation method in enhancing salt tolerance of root system

PendingCN121450694APlant peptidesFermentationBiotechnologyChrysanthemum indicum
The invention belongs to the technical field of genetic engineering, and particularly relates to an agrobacterium rhizogenes-mediated coastal chrysanthemum indicum tissue culture-free genetic transformation method and application thereof in enhancing the salt tolerance of a root system. The agrobacterium rhizogenes-mediated coastal chrysanthemum indicum tissue culture-free genetic transformation method comprises the following steps: transfecting agrobacterium rhizogenes with plasmids containing to-be-transformed gene expression cassettes to obtain recombinant agrobacterium rhizogenes, transfecting stems with terminal buds of coastal chrysanthemum indicum with the recombinant agrobacterium rhizogenes, and then cutting. The method provided by the invention is short in required period, and the transgenic plant can be obtained only in 30-60 days. The problems of long chrysanthemum conversion rate period, complex operation and tedious process are solved. A tissue culture mode is not needed, so that the tedious process of tissue culture is reduced; local materials can be used according to the characteristic of cutting rooting of chrysanthemum, chrysanthemum seedlings do not need to be cultivated from seeds, and time cost is reduced.
Owner:SHANDONG AGRICULTURAL UNIVERSITY

FRET biosensor and preparation method and application thereof

The invention discloses an FRET (Fluorescence Resonance Energy Transfer) biosensor as well as a preparation method and application thereof. The FRET biosensor is obtained by transfecting cells with plasmids for expressing a molecular sensor; the molecular sensor contains NEK7 protein, a fluorescence donor and / or a fluorescence receptor, and the fluorescence donor or the fluorescence receptor is connected to the N end or the C end of the NEK7 protein through a flexible chain. According to the invention, the FRET biosensor is designed, and multiple conditions are optimized, so that the signal response efficiency of the FRET biosensor is improved, and meanwhile, real-time monitoring of NLRP3 oligomerized living cells is realized, and screening of an NEK7-NLRP3 protein interaction interference inhibitor is realized.
Owner:CHINA PHARM UNIV

Stress inducible virus and application thereof

The invention relates to the technical field of medicine and biology, and particularly discloses a stress-inducible virus and application thereof.The stress-inducible virus comprises a stress-inducible adenovirus or a stress-inducible lentivirus, the nucleotide sequence of the stress-inducible adenovirus or the stress-inducible lentivirus is shown as SEQ ID NO: 1, and the nucleotide sequence of the stress-inducible adenovirus or the stress-inducible lentivirus is shown as SEQ ID NO: 2. The preparation method comprises the following steps: constructing a virus vector, wherein the virus vector has a nucleotide sequence as shown in SEQ ID NO: 1; and virus packaging: transfecting HEK293T cells by adopting shuttle plasmids containing SEQ ID NO: 1 and skeleton plasmids containing viral genome sequences, and collecting a virus stock solution to obtain the stress induced virus. The invention also discloses application of the stress-induced virus in preparation of medicines for preventing and treating oral tumors. Controllable release of the foreign protein under a specific signal is realized. The therapeutic protein produced by the invention can maximize the curative effect of drugs such as CD47 targeted protein and the like, and meanwhile, the toxic and side effects of the drugs on other tissues of the whole body are reduced.
Owner:SICHUAN UNIV

Method for efficiently preparing high-purity NudCD3 protein in in-vitro eukaryotic cells

The invention provides a method for efficiently preparing high-purity NudCD3 protein in an in-vitro eukaryotic cell. The method comprises the following steps: synthesizing a target gene; carrying out enzyme digestion on the target gene and the pLEXmMBP vector, and connecting to obtain a recombinant vector; transforming the recombinant vector into competent cells, culturing, and extracting plasmids; transfecting an HEK 293F cell, culturing, and collecting the cell; resuspending the cells in a lysis buffer solution, carrying out ultrasonication and centrifugation, and taking a supernatant; and carrying out affinity chromatography column purification, Prescission protease digestion and molecular sieve purification to finally obtain the NudCD3 protein with the purity of more than 90%. The problems that in the prior art, NudCD3 protein is difficult to express in quantity and insufficient in purity are solved, high-purity protein is provided for structural biology research, drug screening and antibody preparation, and the method has the advantages of being easy to operate, high in yield, high in protein stability and the like.
Owner:ANHUI UNIV

High-affinity anti-carbendazim monoclonal antibody and full-length IgG recombinant antibody expression plasmid thereof

PendingCN122060071AImmunoglobulinsFermentationAntiendomysial antibodiesConstant region gene
The invention discloses a high-affinity anti-carbendazim monoclonal antibody which comprises a heavy chain constant region, a heavy chain variable region, a light chain constant region and a light chain variable region, and the amino acid sequence of a coding gene of the heavy chain variable region is shown as SEQ ID NO: 2; the amino acid sequence of the light chain variable region coding gene is as shown in SEQ ID NO: 4. The invention also discloses a heavy chain expression plasmid of the anti-carbendazim full-length IgG recombinant antibody. The heavy-chain and light-chain variable region gene sequences of the antibody obtained by the invention are respectively connected to expression vectors containing heavy-chain constant region genes and light-chain constant region genes, and the anti-carbendazim full-length IgG recombinant antibody is obtained by adopting mammalian cell expression mediated by a double-plasmid transfection system. Indirect competitive ELISA proves that the expressed recombinant antibody has recognition activity similar to that of a parent monoclonal antibody.
Owner:ZHEJIANG UNIV

Construction method and application of subtilin expression strain

PendingCN122427843APromoterBacilli
The application belongs to the technical field of biology, and discloses a construction method and application of a subtilin expression strain, wherein the recombinant strain is obtained by transfecting a plasmid carrying a spaBTCSIFEGRK whole gene sequence of bacillus subtilis ATCC6633 and containing or not containing an original promoter into BS168 competent cells, so as to obtain a recombinant strain with high expression of subtilin, wherein the recombinant strain has very high safety, a clear genetic background, is easy to be high-density fermented, and has strong protein secretion capacity compared with the original strain.
Owner:SOUTH CHINA AGRICULTURAL UNIVERSITY

DKK-1 antibody biological activity detection method

According to the DKK-1 antibody biological activity detection method provided by the invention, a luciferase expression plasmid containing a TCF-LEF reaction element is transfected into an HEK 293 cell with an active Wnt / beta-catenin signal channel, and a reporter gene detection method based on DKK-1 antibody MOA is successfully established by screening effector cells and optimizing detection conditions. And then carrying out practicability confirmation of the RGA method through condition optimization. The establishment and prediction of the new method can further promote the screening evaluation of DKK-1 antibody drugs and the quality control of the DKK-1 antibody drugs in the subsequent development process, so that an efficient and rapid new method is provided for the biological activity detection of the DKK-1 antibody, and a new thought and direction are provided for the biological activity evaluation of other MOA-based antibodies.
Owner:TAIZHOU MABTECH PHARM CO LTD

VSV rescue

ActiveUS12674143B2Cell culture supernatantPlasmid transfection
The present invention relates to a method for rescue of Vesicular Stomatitis Virus (VSV) from DNA in a HEK293 cell line or a HEK293 cell line adapted to suspension growth comprising (a) providing cells from a HEK293 cell line or a HEK293 cell line adapted to suspension growth in cell culture, (b) transfecting the cells with at least one plasmid, wherein the at least one plasmid comprises (i) an expression cassette comprising a VSV genomic cDNA; (ii) at least one expression cassette encoding VSV nucleoprotein (N) protein, VSV phosphoprotein (P) protein, and VSV large (L) protein; and (iii) an expression cassette encoding SV40 Large T antigen; (c) culturing the transfected cells; and (d) harvesting the cell culture supernatant comprising the rescued VSV. Also provided is the use of a HEK293 cell line or a HEK293 cell line adapted to suspension growth for rescue of Vesicular Stomatitis Virus (VSV) or the use of a plasmid encoding SV40 Large T antigen for rescue of Vesicular Stomatitis Virus (VSV) in a HEK293 cell line or a HEK293 cell line adapted to suspension growth HEK293-F cells by means of transient transfection.
Owner:BOEHRINGER INGELHEIM INT GMBH

Application of SETD1A protein

The present invention belongs to the field of target drug technology, and in particular relates to an application of a SETD1A protein. The amino acid sequence of the SETD1A protein can be found in NCBI under the accession number NP_055527. The SETD1A protein is used as a drug target in the preparation of a drug for treating diseases caused by tobacco-induced DNA damage. By increasing SETD1A expression, for example, SETD1A can be overexpressed by plasmid transfection to repair DNA damage.
Owner:HENAN UNIV OF CHINESE MEDICINE

RAAV generation method

Disclosed herein are improved methods of producing recombinant adeno-associated viruses (rAAVs) for gene therapy. The improved method comprises adding low doses of DMSO and valproic acid to a cell transfected with a plasmid encoding the rAAV and a plasmid containing a cofactor for expressing and / or assembling the rAAV capsid.
Owner:SAREPTA THERAPEUTICS INC

FLNB gene-knockout MDCK cell line, construction method therefor, and use thereof

Provided are an FLNB gene-knockout MDCK cell line, a construction method therefor and the use thereof. The FLNB gene-knockout cell line is named MDCK-FLNB-KO, and has been deposited in China Center for Type Culture Collection (CCTCC) on November 20, 2024, and the accession number is CCTCC NO: C2024391. The FLNB gene knockout uses CRISPR / Cas9 technology, wherein a sgRNA is designed for exon 1 of the FLNB gene of MDCK cells, an FLNB gene knockout vector plasmid 1 and plasmid 2 are constructed, and the plasmid 1 and the plasmid 2 are transfected into the MDCK cells to obtain the FLNB gene-knockout MDCK cell line. Compared with the original MDCK cell line, the obtained cell line has a lower adhesion ability and a higher yield when applied to influenza virus culture.
Owner:WUHAN INST OF BIOLOGICAL PROD CO LTD

FLP-IN-DF-1 cell line as well as construction method and application thereof

The invention relates to the related technical field of molecular biology and cell engineering, in particular to an FLP-IN-DF-1 cell line and a construction method and application thereof, and the construction method comprises the following steps: step 1, constructing CRISPR / Cas9 site-specific cleavage plasmid containing a chicken HIPP11 safety site sequence; step 2, constructing a donor plasmid Donor-FRT containing a homologous arm of a safety site of the HIPP11; 3, jointly transfecting plasmids in the step 1 and the step 2 into a chicken DF-1 cell line to obtain an FLP-IN-DF-1 cell line for expressing red fluorescence; and step 4, under the action of Flp recombinase, transfecting an exogenous gene donor plasmid containing an FRT site to the FLP-IN-DF-1 cell line obtained in the step 3, and driving the expression of a target gene through an optimized strong promoter to realize site-specific transfer and efficient expression of the exogenous gene in the chicken DF-1 cell line. Different from an existing Flp-In system depending on a random integration strategy, the construction method disclosed by the invention emphasizes fixed-point integration and promoter optimization, and improves the homogeneity, stability and screening efficiency of exogenous gene expression.
Owner:CHINA AGRI UNIV

Fixed-point efficient knock-in Vero cell line of targeted AAVS1 safe port and use method of fixed-point efficient knock-in Vero cell line

The invention relates to the technical field of gene editing, in particular to a targeted AAVS1 safe port fixed-point efficient knock-in Vero cell line and a use method thereof.A safe port in a Vero cell is searched and confirmed, and finally it is confirmed that the position where AAVS1 in Vero is located is Genebank: NC132909. The method comprises the steps that an editing sequence is connected with PE editing plasmids, and transfecting the editing plasmid and the working plasmid into a Vero cell line, and carrying out antibiotic pressurized screening to obtain a cell line in which the attP sequence is knocked at the AAVS1 site. And on the other hand, the gene editing fixed-point insertion method used in the research provides a new thought for gene engineering modification and construction of the cell line, and has important significance for biological research of targeted insertion.
Owner:INST OF MEDICAL BIOLOGY CHINESE ACAD OF MEDICAL SCI

In-vitro stable subculture construction method of yak ovarian granular cell line

The invention discloses an in-vitro stable subculture construction method of a yak ovarian granular cell line. Relates to the technical field of cell culture. Comprising the following steps: carrying out subculture and amplification on primary yak ovarian granular cells to obtain yGCs; and carrying out pCI-neo-hTERT plasmid transfection and establishment of a monoclonal cell. The immortalized yGCs constructed by using an hTERT plasmid method can provide infinitely proliferated homogenized cells, reduce damage to yaks and avoid individual differences, can retain the core function of regulating follicular development of yGCs, provides a high-quality model for analyzing molecular mechanisms such as seasonal oestrus and low reproduction efficiency of yaks, and has theoretical and application values.
Owner:TIBET AGRI & ANIMAL HUSBANDRY COLLEGE

Method for researching regulation and control of variant antigen gene of plasmodium non-coding RNA (Ribonucleic Acid)

PendingCN121160696AProtozoaMicroorganism based processesEnzyme digestionPlasmodium falciparum
The invention relates to the technical field of non-coding RNA (Ribonucleic Acid) of parasites, and discloses a method for researching regulation and control of variant antigen genes of plasmodium non-coding RNA, which comprises the following steps: S1, constructing a modified plasmid pLN-ENR-GFP by overexpression plasmid: replacing a promoter region with a plasmodium falciparum U6 promoter; after PCR amplification, carrying out HindIII / EcoRI double enzyme digestion on a product, and inserting the product into a pLN-ENR-GFP carrier; adding a 9 * T terminator at the 3'end, introducing EcoRI / ApaI enzyme cutting sites at the two ends, and carrying out enzyme cutting connection: inserting an RUF6-15 fragment into the modified pLN-ENR-GFP vector; s2, synchronization of plasmodium and plasmid transfection and synchronization: taking a plasmodium falciparum in-vitro culture with a plasmodium falciparum body proportion of more than 60% in a cyclic body stage, and adding 5% of D-sorbitol (1 ml of cell volume: 14 ml of sorbitol); according to the method for researching the regulation and control of the variant antigen gene of the plasmodium non-coding RNA, a plasmodium falciparum RUF6-15 transgenic overexpression strain (138nt) is constructed, efficient and stable expression of target ncRNA is realized through optimization of a U6 promoter (SEQ ID NO: 1) and a PolyT terminator, and the technical bottleneck of functional verification of medium-length ncRNA of the plasmodium is broken through.
Owner:INSTITUTE OF BASIC MEDICAL SCIENCES CHINESE ACADEMY OF MEDICAL SCIENCES

Method for constructing stable cell strain capable of inducing gene silencing based on Piggybac system

The invention relates to a method for constructing a stable cell strain capable of inducing gene silencing based on a Piggybac system. In particular, the present disclosure provides an engineered transposable element based on Piggybac comprising, from 5'to 3 ': a 5' ITR, a transposed region, a 3 'ITR. According to the present invention, the promoter, the Tet operon, the TetR, the shRNA design, the recombinant plasmid construction, the plasmid transfection and other aspects are optimized, such that the delivery, the integration and the validity verification of the Piggybac system-based induced gene silencing are achieved, the precise control and the reversible operation of the target nucleic acid expression level are achieved, and the quantitative data of the highly controllable silencing system is provided.
Owner:NAT INST OF PHARMA R & D CO LTD

Method for preparing cat-induced pluripotent stem cells

ActiveCN118389596BPluripotential stem cellLIN28
The application discloses a preparation method of cat induced pluripotent stem cells, which comprises the following steps: constructing piggyBac transposon plasmids carrying cat source OCT4, SOX2, KLF4 and c-MYC four factors in series, piggyBac transposon plasmids carrying cat source or pig source NANOG and LIN28 two factors in series and piggyBac transposon plasmids carrying monkey kidney virus SV40LT plasmids, and transfecting the plasmids into cat fetal fibroblasts; picking up cloned cells with embryonic stem cell morphologies, and carrying out subculture of cell clones meeting the characteristics of embryonic stem cells through identification and screening, so that the cat induced pluripotent stem cells are obtained. The preparation method of the cat induced pluripotent stem cells is safe, efficient and has good differentiation potential, lays a scientific foundation for researching in-vitro culture conditions of feline ESCs and establishment of feline iPSCs, and lays a scientific foundation for further cultivating cloned cats and gene modified cats and researching in related disease mechanisms, screening drugs and regeneration and repair.
Owner:SHANXI AGRI UNIV

Construction method of human adenovirus type 4 protein v knockout mutant strain and application thereof

PendingCN122357461ASecondary InfectionsWild type
The application discloses a construction method of a human adenovirus type 4 protein V knockout mutant strain and application thereof, and belongs to the technical field of biotechnology. The application precisely knocks out a protein V coding sequence in a human adenovirus type 4 full-genome infectious clone by means of a Red / ET homologous recombination system combined with a ccdB reverse screening technology, and obtains a recombination plasmid pBR322-Ad4-△V-EGFP which is clear in genetic background and highly homozygous in sequence. After the plasmid is transfected into HEK-293 cells, the human adenovirus type 4 protein V knockout mutant strain obtained exhibits a typical “replication-deficient” phenotype: although a particle containing a viral genome can be packaged, the physical titer (4.76×10 6 copies / μL) of the particle is about one order of magnitude lower than that of a wild type, and the progeny virus completely loses secondary infection ability. Transcriptome analysis reveals that the deletion mutation can specifically down-regulate a host proteasome pathway and activate a natural immune response. The mutant strain is high in safety and strong in immunogenicity, and can be used as an ideal attenuated vaccine carrier or a gene therapy tool.
Owner:ACADEMY OF MILITARY MEDICAL SCIENCES

Cell line for stably expressing porcine delta coronavirus S protein, porcine delta coronavirus IgA antibody detection antigen and kit

The invention discloses a cell line for stably expressing porcine delta coronavirus S protein, a porcine delta coronavirus IgA antibody detection antigen and a kit. The method comprises the following steps: based on an S protein sequence of a CH / XJYN / 2016 strain, selecting an extracellular domain part D20-N1077, adding a human source septoglobin family 1D meber 1 signal peptide sequence MRLSVCLLLTLALCCYRANA to an amino terminal of the S protein, adding a 6 * His tag sequence to a carboxyl terminal, carrying out codon optimization according to a CHO expression system, and constructing into a pCDNA3.1 (+) eukaryotic expression vector to obtain a recombinant eukaryotic expression plasmid pcDNA3.1 (+)-PDCoV-S; then transfecting CHO cells with the plasmid, and carrying out two rounds of heredity mycin G418 pressurized screening, limited dilution cloning and continuous subculture to obtain an expiCHO-PDCoV-S stably transfected cell line through screening; and finally, constructing the PDCoV IgA antibody detection kit based on the cell line. The kit has no cross reaction with other common porcine disease virus positive serum, has intra-batch and inter-batch variation coefficients of less than 10%, has good specificity, repeatability and sensitivity, and can be used for early prevention and control of PDCoV.
Owner:LANZHOU VETERINARY RESEARCH INSTITUTE CHINESE ACADEMY OF AGRICULTURAL SCIENCES(LANZHOU BRANCH CENTER OF CHINA ANIMAL HEALTH & EPIDEMIOLOGY CENTER)

Grass carp brain astrocyte cell line and application thereof

The present application relates to the field of cytology, in particular to a grass carp brain astrocyte cell line and its application, which was preserved in China Center for Type Culture Collection on May 7, 2025, and the preservation number is CCTCC NO: C2025149. The grass carp brain astrocyte cell line provided by the present application has the ability to efficiently proliferate GCRV-II, and the virus titer of GCRV-II replicated in the cell line can reach at least 1.38x10 8 pfu / mL or more; the virus of GCRV-II after blind transmission for 5 generations in the grass carp brain astrocyte cell line can still cause typical hemorrhagic symptoms and death in grass carp. And the transfection efficiency of the grass carp brain astrocyte cell line transfected with exogenous plasmid is similar to that of commercial grass carp kidney cells. Therefore, the present application lays an important foundation for in-depth study of the pathogenic mechanism of GCRV-II, vaccine preparation, antiviral drug screening, and prevention and control of grass carp viral hemorrhagic disease.
Owner:INST OF AQUATIC LIFE ACAD SINICA

Method for preparing human lysozyme exosome fusion protein based on immortalized bovine mammary epithelial cells and application of human lysozyme exosome fusion protein

The invention belongs to the technical field of biology, and particularly relates to a method for preparing human lysozyme exosome fusion protein based on immortalized bovine mammary epithelial cells and application of the human lysozyme exosome fusion protein. The method comprises the following steps: acquiring and purifying primary bovine mammary epithelial cells; transfecting an hTERT gene to construct an immortalized cell line; constructing an expression plasmid containing the fusion gene of the CD47 ankyrin and the human lysozyme; transfecting plasmids into immortalized cells, and screening positive clones; and finally, separating the human lysozyme exosome fusion protein from the cell culture supernatant by using a Ni-NTA chromatographic column to obtain the human lysozyme exosome fusion protein. The fusion protein has lysozyme activity, can effectively dissolve bacteria, has antibacterial and anti-inflammatory functions, is high in stability and low in antigenicity and is suitable for preparing antibacterial or anti-inflammatory drugs, immortalized cells are used as a bioreactor, efficient and continuous secretion of human lysozyme is achieved, and the human lysozyme can be used for preparing antibacterial or anti-inflammatory drugs. The problems of low yield, poor activity and insufficient stability in the traditional method are solved.
Owner:INNER MONGOLIA UNIVERSITY +1

Optimized cell transplant, and preparation method and use thereof

Disclosed in the present invention is an optimized cell transplant. The optimized cell transplant is formed by performing gene induction and modification on a mesenchymal stem cell in the form of a small molecule and protein composition. The expression levels of CD200 gene, Galectin-9 gene and VISTA gene can be increased synchronously after cell culture. Vector virus infection and plasmid transfection are not required in the cell preparation process, so that high biological safety and great clinical application value of cells are achieved. The optimized cell transplant is suitable for the technical field of mesenchymal stem cells applied to cell transplantation therapy, and the therapeutic effect of the optimized cell transplant is more excellent than that of the non-modified mesenchymal stem cell.
Owner:GWOXI STEM CELL APPL TECH CO LTD

Preparation method and application of an oral engineering probiotic system for producing active substances in situ metabolic chemotherapy of tumors

PendingCN122398867AImprove the effect of chemotherapyPromote accumulationCarboxylic acidPharmaceutical Substances
The application aims to provide a preparation method and application of an oral engineering probiotic system for producing active substances in situ metabolism of tumors. First, the probiotic is cultured, the CES gene is inserted into a plasmid as a target gene, the plasmid containing the CES gene is transfected into a probiotic competent cell by a heat shock method, the engineering probiotic capable of continuously and stably expressing carboxylesterase is obtained, and the oral engineering probiotic system is prepared by coating the engineering probiotic with a natural high molecular material, mercapto hyaluronic acid. The preparation method is scientific and reasonable, raw materials are abundant, and the preparation is easy to produce. The preparation method enhances the chemotherapy effect of colorectal cancer and reduces the toxic side effects caused by the distribution of chemotherapy drugs in other tissues and organs, provides new technical support for the treatment of colorectal cancer, is an innovation in oral microecological preparation drugs, and has great economic and social benefits.
Owner:ZHENGZHOU UNIV

Improved recombinant adeno-associated virus production

Application of adeno-associated virus (AAV) vectors in large animal studies and clinical trials often requires high-titer and high-potency vectors manufactured at a scale that can support large doses and / or large populations. A number of currently used vector production methods, based on either transient transfection or helper virus infection of cell lines, have their advantages and limitations. Here we report novel methods and compositions for high-titer AAV production with several key improvements and advantages: (1) a one-step cloning of therapeutic AAV vector cassette into the serotype-specific packaging plasmid; (2) a single plasmid transfection and selection for stable AAV vector producer cell lines.
Owner:BRAMMER BIO LLC

Turbot gill tissue cell line and application thereof

The present invention provides a turbot gill cell line, which has a deposit number of CCTCCNO: C2022230. The turbot gill tissue cell line SMG provided by the present invention can be continuously passaged. Experimental results show that it can be passaged up to 65 generations and remains stable, and can provide a large number of stable turbot gill cells for the study of immune function genes. The provided cell line has excellent properties and is a fibroblast. The cells are spindle-shaped or irregularly triangular, with several irregular protrusions extending outward from the cell body, and the cells are closely arranged. It is passaged once every 3-4 days, has high recovery efficiency, and can be used for plasmid transfection, siRNA interference and other molecular biology experiments.
Owner:QINGDAO AGRI UNIV

An anti-acetamiprid monoclonal antibody and a recombinant full-length IgG expression plasmid thereof

The application discloses an anti-acetamiprid high-affinity and high-specificity monoclonal antibody, an amino acid sequence of a heavy chain variable region of mAb-QA1 is shown as SEQ ID NO: 2, and an amino acid sequence of a light chain variable region of mAb-QA1 is shown as SEQ ID NO: 4. The application also discloses an expression plasmid of an anti-acetamiprid full-length IgG recombinant antibody. The variable region sequence genes obtained by the application are connected to expression vectors containing heavy chain constant region genes and light chain constant region genes respectively, double-plasmid transfection is adopted, and the anti-acetamiprid full-length IgG recombinant antibody is obtained based on mammalian cell expression and purification, and it is proved by indirect competitive ELISA analysis that the expressed recombinant antibody has similar detection activity to the parent monoclonal antibody. The antibody heavy and light chain variable region sequences and the recombinant expression plasmids thereof can be applied to the stable production of batches of the anti-acetamiprid full-length IgG recombinant antibody, and provide reliable and stable core reagents for the construction of an immune analysis method for acetamiprid residues in the environment and food and the development of precise and rapid measurement products.
Owner:ZHEJIANG UNIV